Top Suppliers:I want be here




41639-83-2

41639-83-2 structure
41639-83-2 structure
  • Name: LatanoprostAcid
  • Chemical Name: latanoprost free acid
  • CAS Number: 41639-83-2
  • Molecular Formula: C23H34O5
  • Molecular Weight: 390.513
  • Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
  • Create Date: 2018-07-11 15:40:39
  • Modify Date: 2024-01-11 12:51:01
  • Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2].

Name latanoprost free acid
Synonyms (5Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
Latanoprost acid
latanoprost free acid
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-, (5Z)-
LatanoprostAcid
(5Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}-5-heptenoic acid
Description Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor[1]. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes[2].
Related Catalog
Target

FP

In Vitro Latanoprost acid (10-20 μM;24 hours) reduces he protein expressions of c-fos and NFATc1[1]. Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK[1]. Latanoprost acid (10 μM, 20 μM) significantly inhibits the mature osteoclast formation[1]. Western Blot Analysis[1] Cell Line: Bone marrow-derived macrophages cells (BMMs) Concentration: 10 μM, 20 μM Incubation Time: 24 hours Result: Reduced he protein expressions of c-fos and NFATc1.
In Vivo Latanoprost acid (i.p.; 20 mg/kg; once a day for 7 days) notably prevents LPS-induced bone destruction at a dose of 20mg/kg[1]. Animal Model: 8-week-old C57BL/6J mice[1] Dosage: 20 mg/kg Administration: Intraperitoneally injected; once a day for 7 days Result: Notably prevented LPS-induced bone destruction at a dose of 20mg/kg.
References

[1]. Weinreb RN, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S53-64.

[2]. Xu X, et al. The prevention of latanoprost on osteoclastgenesis in vitro and lipopolysaccharide-induced murine calvaria osteolysis in vivo. J Cell Biochem. 2018 Jun;119(6):4680-4691.

Density 1.2±0.1 g/cm3
Boiling Point 609.1±50.0 °C at 760 mmHg
Molecular Formula C23H34O5
Molecular Weight 390.513
Flash Point 336.2±26.6 °C
Exact Mass 390.240631
PSA 97.99000
LogP 2.22
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.564
Storage condition -20°C
Personal Protective Equipment Eyeshields;Gloves
RIDADR NONH for all modes of transport